Parexel has become the latest CRO to be bought up as the industry continues its M&A bonanza.

LabConnect has received a healthy $24.5 million in its first equity investment.

Probably hoping to help turn things around after clinical setbacks, microRNA biotech Regulus tapped the help of CRO Aptuit.

Eisai and partner Charles River have clearly enjoyed their two-year R&D deal, as the pharma-CRO pair have signed up to extend that partnership for another…

DelMar is advancing its first-in-class brain cancer med dianhydrogalactitol (VAL-083) into phase 3, and it has recruited PRA Health Sciences to conduct that…

CRO Clinigen is teaming up with biotech Tesaro and its PARP ovarian cancer med niraparib to help launch an early access program in Europe, coming after the…

Quintiles and IMS Health came together last year in a massive $19 billion megamerger, and now INC and inVentiv are looking to follow suit, combining into one…

Not a week seems to go by without a CRO sale rumor, and now the Wall Street Journal is adding Parexel to that list.

Asia-Pacific CRO George Clinical has topped up its cancer services and boosted its U.S. presence after acquiring Memphis, Tennessee-based Vector Oncology'…

R&D